alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

News

What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.

Find news

1 of 347 news items, newest first.

Free to read, “May need a subscription” and “Archived copy”: what they mean

Whether an article is free to read is a guess, not a test of your access. Each item is one of three:

  • No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
  • May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
  • “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.

Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.

Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release

Alzheimer's Association Research

Novo Nordisk's EVOKE and EVOKE+ Phase 3 trials of oral semaglutide in more than 3,800 people with early symptomatic Alzheimer's did not meet the primary endpoint of significantly slowing disease progression, despite improving some Alzheimer's-related biomarkers. Novo Nordisk ended its Alzheimer's trials for semaglutide, including the injectable version.

Why it matters: A high-profile failure for the theory that GLP-1 weight-loss drugs could treat Alzheimer's, dampening near-term hopes for repurposing this popular drug class for dementia.

Read at Alzheimer's Association → Archived copy (30 Jul 2026), Internet Archive

Follow new items in a feed reader: Atom feed.